← Leaderboards
Nicholas John Izzo
Cognition Therapeutics, Inc.
$4,437,830
Attributed
$4,437,830
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.8M · FY2015–20$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$4,437,830 · 4
By mechanism
R42$2,126,690 · 1
R44$1,788,611 · 1
R41$522,529 · 2
Top collaborators
No co-investigators on record.
Most similar at Cognition Therapeutics, Inc.
Same institution · by research overlap
- Susan M Catalano$36,630,926
- Anthony O Caggiano$51,394,003
- Paul S. Aisen$209,920,520
- Christopher H Van Dyck$43,230,259
- Mary E Hamby$9,832,688
Others in their field
Top investigators on “Abeta Oligomer”
- Anthony O Caggiano · Cognition Therapeutics, Inc.$49,842,374
- Susan Abushakra · Alzheon, Inc.$47,690,244
- Susan M Catalano · Cognition Therapeutics, Inc.$31,571,392
- Paul S. Aisen · Cognition Therapeutics, Inc.$25,787,271
- Christopher H Van Dyck · Cognition Therapeutics, Inc.$24,529,670
- Stephen M Strittmatter · Yale University$16,438,796
Research focus
Abeta OligomerS DiseasePharmaceutical PreparationsSynapsesMouse ModelBrainImpaired CognitionAlzheimer&AposDoseNeuronsReceptorProteinsAmyloid Beta-ProteinSigma-2 ReceptorBinding SitesCognitive PerformanceSitePharmaceutical ChemistryPathologyPharmacologic SubstanceCerebrospinal FluidBindingLigandsProtein Complex
Grant awards (7)
Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways$729,226
R44 · FY2020 · AG · contact PI
Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction$1,072,222
R42 · FY2019 · AG · contact PI
Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways$699,266
R44 · FY2019 · AG · contact PI
Optimization of sigma-2 receptor modulators for the treatment of cognitive dysfunction$1,054,468
R42 · FY2018 · AG · contact PI
Mechanism of action of oligomer-displacing Alzheimer investigation drug, CT1812:Receptor interactions and signaling pathways$360,119
R44 · FY2018 · AG · contact PI
New piperazines effecting Abeta oligomer displacement from neuronal receptors$224,002
R41 · FY2016 · AG · contact PI
Novel sigma-2 receptor modulators for the treatment of cognitive dysfunction$298,527
R41 · FY2015 · AG · contact PI